Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
SAN DIEGO, July 17, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a...
Pharmaceutical
OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain
LONDON and NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which...
Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas
- Announces Completion of Phase 1 Study of Elraglusib in Pediatric Patients - Prolonged and Durable Complete Responses (CRs) Observed...
Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer
Dr. Zuraw led clinical development of telitacicept across MG, Sjögren’s, SLE, and RA at RemeGen, resulting in multiple regulatory approvals...
BioNTech Announces Ryan Richardson to Step Down from the Management Board
MAINZ, Germany, July 17, 2025 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that Ryan...
Gelteq Announces Agreement with IDT Australia to Secure Dedicated New Product Development and Manufacturing Facilities
Partnership to support the scale-up and commercialization of Gelteq’s proprietary gel-based oral delivery platformNEW YORK, July 17, 2025 (GLOBE NEWSWIRE)...
Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships
Moleculin Biotech, Inc. Adriano Treve 40+ year career at Roche founded on dedication to bringing new innovative medicines to patients...
60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella Bacteria
Study will evaluate activity of tafenoquine against vector-borne pathogens, Borrelia (Lyme disease) and Bartonella in cell cultureBorrelia and Bartonella, together...
Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update
Compelling new preliminary data consistent with previously reported preclinical findings demonstrating certepetide’s potential ability to enhance the effectiveness of immunotherapyBASKING...
Hyperion DeFi to Host Corporate Update Event to Discuss Strategic Evolution from Eyenovia and the Future of On-Chain Finance on July 29, 2025
LAGUNA HILLS, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), today...
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies
The Breakthrough Therapy Designation (BTD) was granted based on the highly compelling results from the Phase 2 EMBOLD trial in...
Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept
Milestone payment of $10 million triggered under the global license agreement with TakedaLEXINGTON, Mass., July 17, 2025 (GLOBE NEWSWIRE) --...
Repligen to Report Second Quarter 2025 Financial Results
Webcast and Conference Call to Be Held Tuesday, July 29, 2025, at 8:30 a.m. ETWALTHAM, Mass., July 17, 2025 (GLOBE...
Velocity Clinical Research Partners with Palantir to Solve Clinical Trials’ Payment Headache
Raghu Punnamraju, Velocity Clinical Research Chief Technology Officer Raghu Punnamraju, Velocity Clinical Research Chief Technology Officer DURHAM, N.C., July 17,...
Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline
- Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases...
Harvard Bioscience Announces CEO Succession Plan & Appointment of Two New Independent Directors to Board
Current Board member John Duke to succeed Jim Green as President & CEO Rob Gagnon and Seth Benson appointed as new Board...
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
Company to participate in investor conferences in July and AugustVANCOUVER, British Columbia, July 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc....
Immuron – FY25 global sales exceed projection, up 49% on prior year
Sales Highlights (unaudited): Global Annual sales AUD$7.3 million up 49% on prior yearJune 2025 Quarter AUD$2.0 million up 55% on...
Ascentage Pharma Announces Closing of Placement Shares in Top-Up Placement
ROCKVILLE, Md. and SUZHOU, China, July 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage...
Pharming Group to report second quarter and first half 2025 financial results and provide business update on July 31
Leiden, the Netherlands, July 17, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary...